Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial

NCT04417036 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04417036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04417036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Terminated
Start date
July 7, 2020
Completion date
December 28, 2022
Enrollment
90 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome